wmm, Author at Invivoscribe

About wmm

This author has not yet filled in any details.
So far wmm has created 69 blog entries.

JAMT

wmm2025-02-27T18:10:35-08:00May 10th, 2024|Conferences|

BSH

wmm2025-02-27T18:10:11-08:00April 27th, 2024|Conferences|

AACR

wmm2025-02-27T18:09:58-08:00April 25th, 2024|Conferences|

EHA Balkan Day

wmm2025-02-27T18:09:38-08:00April 25th, 2024|Conferences|

AMP Middle East

wmm2025-02-27T18:08:52-08:00April 12th, 2024|Conferences|

15th World CB & CDx Summit Europe

wmm2025-02-27T18:08:30-08:00April 8th, 2024|Conferences|

USCAP

wmm2025-02-27T18:07:19-08:00March 22nd, 2024|Conferences|

Bio-Europe Spring

wmm2025-02-27T18:06:41-08:00March 17th, 2024|Conferences|

Precision Med Tri-Con

wmm2025-02-27T18:06:21-08:00March 11th, 2024|Conferences|

JSMO 2025

wmm2025-02-27T18:05:49-08:00March 6th, 2024|Conferences|

EHA 47th JSTCT

wmm2025-02-27T18:05:22-08:00February 27th, 2024|Conferences|

Leveraging Standardized MRD Assays to Guide CLL Treatment

wmm2024-01-25T10:44:11-08:00January 25th, 2024|2024 Publications, Featured Publications, Publications|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

wmm2023-04-10T20:22:16-07:00March 23rd, 2023|2023 Publications, Featured Publications, Publications|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

wmm2023-04-10T20:24:04-07:00March 2nd, 2023|2023 Publications, Featured Publications, Publications|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21-08:00November 15th, 2022|2022 Publications, Featured Publications, Publications|

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

wmm2023-01-16T21:30:16-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

wmm2023-01-16T21:27:56-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

wmm2022-10-27T04:25:21-07:00October 26th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML

wmm2022-10-24T14:57:12-07:00October 24th, 2022|2022 Press Releases, Press Releases|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

wmm2022-12-29T21:19:31-08:00June 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

wmm2023-01-08T18:20:36-08:00May 30th, 2022|2022 Publications, Featured Publications, Publications|

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine

wmm2022-05-09T17:27:05-07:00May 9th, 2022|2022 Press Releases, Press Releases|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

wmm2022-01-06T05:38:03-08:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

wmm2022-01-08T23:37:03-08:00December 28th, 2021|2021 Publications, Publications|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

wmm2022-01-04T04:43:02-08:00December 8th, 2021|2021 Publications, Publications|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About wmm

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.